Showing results (21-30 of 45) with videos related to
Sort By:
Pageof 5
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 30, 2019
Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug DevelopmentWalter Reinisch, Klaus Gottlieb, Jean-Frederic Colombel, et al.The American Journal of Gastroenterology|August 17, 2011
The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safetyGert Van Assche, James D Lewis, Gary R Lichtenstein, et al.Journal of Crohn'S & Colitis|August 5, 2016
Evolving Concepts in Phases I and II Drug Development for Crohn's DiseaseVipul Jairath, Barrett G Levesque, Niels Vande Casteele, et al.Journal of Crohn'S & Colitis|June 20, 2018
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 StudyBruce E Sands, William J Sandborn, Brian G Feagan, et al.Journal of Crohn'S & Colitis|April 25, 2015
Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD InitiativeSilvio Danese, Gionata Fiorino, Jean-Yves Mary, et al.Nature Communications|August 30, 2020
Integrated microbiota and metabolite profiles link Crohn's disease to sulfur metabolismAmira Metwaly, Andreas Dunkel, Nadine Waldschmitt, et al.Gastroenterology|March 31, 2018
Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's DiseaseSilvio Danese, Stefanos Bonovas, Anthony Lopez, et al.Journal of Crohn'S & Colitis|February 14, 2012
Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensusWalter Reinisch, Gert Van Assche, Ragnar Befrits, et al.Alimentary Pharmacology & Therapeutics|April 27, 2022
Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE StudyNiels Vande Casteele, William J Sandborn, Brian G Feagan, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 18, 2024
A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative ColitisSilvio Danese, Michael E Rothenberg, Jeremy J Lim, et al.Pageof 5